SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong quarterly results and raised outlook have been overshadowed by a sharp selloff, with traders focused on negative cash flow, heavy spending to expand production, and valuation after the stocks run-up. Bulls call the decline an overreaction and point to demand for data-center power, while bears question whether growth will translate into cash generation.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics early Phase 1 azer-cel results in progressive MS are driving attention, with traders highlighting encouraging safety and signs of disability stability or improvement as a potential pipeline opportunity beyond BRIUMVI. Others say the stock reaction has been underwhelming and caution that the findings come from a small, uncontrolled study; BRIUMVIs subcutaneous trial data and earnings are also in focus.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Anticipation of Anthropics potential IPO and related S-1 filing is driving attention, with traders viewing DXYZ as a public-market proxy for its private-company holdings and debating whether those holdings support a higher NAV. Bullish excitement over a possible IPO-fueled rerating is tempered by concerns about delays, weak price action, and the gap between estimated NAV and the share price.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEPs steep decline has traders focused on whether its high distribution is sustainable, with speculation about a cut and concern over hedging losses, debt maturities, and upcoming earnings. Some see value in IEPs CVR Energy stake and potential short-squeeze dynamics, while others argue that continued losses and dilution outweigh the distribution.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

BDR Pharmaceuticals lawsuit challenging the FDAs refusal to accept a generic application for VOQUEZNA has raised concerns that Phathoms exclusivity could be shortened, weighing on shares. Traders debate how serious the risk is: some see a long-term overhang, while others stress the suit is not approval of a generic and expect the FDAs exclusivity decision to stand.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express shares are drawing attention after quarterly results beat profit expectations and the company raised its earnings outlook, but revenue fell slightly short and plans to cut about 5% of its global workforce as part of a restructuring. Traders are divided: some see the selloff as excessive given the stronger guidance, while others focus on the revenue miss, layoffs, and consumer-spending concerns.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs steep decline toward fresh lows is driving a largely bearish discussion, with traders tying the pressure to doubts about the companys value and dilution as well as Trump-linked political and Iran-war headlines. Some point to a possible technical floor or bounce, but the dominant tone is skepticism about the stocks prospects.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martins quarterly earnings beat, raised outlook, record backlog and 10-year F-35 framework for 850 aircraft are driving attention, reinforcing the defense-demand growth story. Traders are largely bullish on the move, though some warn the sharp rally may be overbought and vulnerable to a pullback.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

A sharp gold selloff has put GLDs safe-haven role under scrutiny, with traders pointing to dollar and rate concerns and its recent tendency to fall alongside risk assets; others see the pullback near support as a buying opportunity.

Bitdeer Technologies Group engages in the cryptocurrency mining industry. It generates income through its proprietary mining datacenters. The firm handles complex processes involved in computing such as equipment procurement, transport logistics, datacenter design and construction, equipment management, and daily operations. The company was founded by Wu Jihan in December 2021 and is headquartered in Singapore.

Bitdeer Technologies Group. - Ordinary Shares - Class A

Bitdeer Technologies Holding Co

BTDR is drawing attention for a steep selloff and persistent underperformance versus other bitcoin miners, even as traders point to its bitcoin production growth and AI/data-center contracts. The community debates whether dilution concerns, heavy short interest, or broader weakness in crypto and AI infrastructure stocks are weighing on shares, while some investors view the decline as a buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology

NeoGenomics, Inc. (NASDAQ: NEO), a provider of oncology diagnostic solutions that enable precision medicine across the cancer care continuum, has expanded its partnership with Indica Labs, a global leader in AI-powered digital pathology. The collaboration is intended to scale NeoGenomics' digital...

NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026. Company management will...

What's Going On With NeoGenomics Stock Tuesday?

NeoGenomics stock falls after leadership shuffle and Q3 preliminary results. Analysts weigh in on growth and valuation.read more...

This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Analysts upgraded Boyd Gaming, NeoGenomics, PENN Entertainment, XP and Rezolute, raising targets for several names.read more...

NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan

NeoGenomics, Inc. (NeoGenomics or the Company) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that as part of a planned succession, its Board of Directors has appointed Warren Stone, current President and Chief Operating Officer...

Why Women-Run Companies Deserve a Place in Your Portfolio

BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.

Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

3 Promising Genomics Stocks in the Spotlight in 2026 

Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.

NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that the Company will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, which is being held Sept. 1416, 2026, in New York, NY.Managements...

Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today? 

Equity

Earnings, drug development, and healthcare reimbursement fueled the stock rallies. 

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Neogenomics Inc.

Neutral Sentiment

<ul class="summary-bullets"><li>J.M. Smucker climbed to nearly a three-year high of $134.85 after the company posted better-than-expected fiscal 2027 first-quarter results.&nbsp;</li><li>JPMorgan kept an ‘Overweight’ rating on Replimune and raised its price target to $21 from $20.&nbsp;</li><li>NeoGenomics secured expanded Medicare coverage for its RaDaR ST liquid biopsy test.&nbsp;</li></ul><p>J.M. Smucker Co. (SJM), Replimune Group (REPL) and NeoGenomics (NEO) hit fresh 52-week highs on Wednesday, fueled by company-specific catalysts. Improving volumes at Smucker, clinical momentum at Replimune and Medicare coverage for NeoGenomics’ cancer test gave investors fresh reasons to buy.&nbsp;</p><p>J.M. Smucker and NeoGenomics stocks gained over 4% and 3%, while Replimune stock climbed 0.5%.&nbsp;</p><h2 class="st-heading-2">J.M.&nbsp;Smucker Gains On Improving Volumes</h2><p><a href="https://stocktwits.com/symbol/SJM">J.M. Smucker stock</a> reached nearly a three-year high of $134.85 after the packaged-food company delivered stronger-than-expected first-quarter fiscal 2027 results. The performance prompted BTIG to increase its price target to $150 from $130 while keeping a ‘Buy’ rating.</p><p>The key signal for investors was a recovery in underlying product volumes. With Hostess excluded, each of Smucker’s operating businesses posted volume gains during the quarter. The company’s Q2 revenue of $2.2 billion and earnings of $3.24 both exceeded analysts' consensus expectations of $2.1 billion and $2.2 per share, respectively, according to Fiscal Ai data.&nbsp;</p><p>On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory.&nbsp;</p><h2 class="st-heading-2">Replimune Builds On Clinical Momentum</h2><p><a href="https://stocktwits.com/symbol/REPL">Replimune stock</a> climbed to an annual high of $15.99 as investors continued to respond to developments surrounding its cancer-treatment pipeline. JPMorgan raised its price target to $21 from $20 and maintained an ‘Overweight’ rating.</p><p>The firm pointed to support from key opinion leaders for the company’s approach to treating melanoma patients whose disease has stopped responding to PD-1 therapies. Replimune’s Tudriqev program has emerged as an important part of that opportunity as the company advances through major regulatory approvals.</p><p>Retail sentiment around the stock remained in ‘bullish’ territory.&nbsp;</p><h2 class="st-heading-2">NeoGenomics Gets A Reimbursement Boost</h2><p><a href="https://stocktwits.com/symbol/NEO">NeoGenomics stock</a> also reached a new 52-week high of $17.45. The company received a Medicare coverage determination for its RaDaR ST liquid biopsy test, which is designed to help detect minimal residual disease and assess treatment response.</p><p>Medicare reimbursement could make it easier for physicians to include the test in cancer care. The decision could expand NeoGenomics' commercial opportunity by reducing a major hurdle to wider adoption by oncology practices. However, retail sentiment around the stock remained in ‘bearish’ territory.</p><p>So far this year, SJM, REPL and NEO stocks have gained between 33% and 63%.&nbsp;</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anf-stock-is-on-fire-after-strong-q2-why-jefferies-still-sees-18-more-upside/cZY8mnGRJpO">ANF Stock Is On Fire After ‘Strong Q2’ — Why Jefferies Still Sees 18% More Upside</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, a hand holds a smartphone displaying the logo of The J.M. Smucker Company.

Earnings, drug development, and healthcare reimbursement fueled the stock rallies.

Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?

Replimune Group Inc

J.M. Smucker Co.

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$16.61
Prev Close	$16.39
Open	$16.25
Dividend Yield	0.00%
50-Day Moving Average	$17.56
Beta	1.31
Avg. Volume	2.05M
PE Ratio	-40.63

52-Week High	$20.15
52-Week Low	$7.07
Market Capitalization	$2.11B
EPS (Annual)	-$0.8433
Price to Book	2.67
Revenue Per Employee	$290,932.80

Feed

News

Sentiment

Earnings

Fundamentals

Info

NEO Fundamentals